Skip to content
GHRH analogues

Sermorelin vs CJC-1295 vs Tesamorelin

The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.

What it is
SermorelinGrowth-hormone-boosting peptide that prompts the pituitary gland; previously approved for childhood growth hormone deficiency.
CJC-1295Experimental long-acting peptide that raises growth hormone (GH) levels; only small studies in humans.
TesamorelinApproved medicine for HIV-related lipodystrophy that reduces the belly fat around internal organs.
Type
SermorelinShortened version of growth hormone-releasing hormone (GHRH)
CJC-1295Modified growth hormone-releasing hormone, long-acting
TesamorelinModified version of growth hormone-releasing hormone (GHRH)
Structure
SermorelinFragment of GHRH made of its first 29 amino acids
CJC-129530 aa + DAC (maleimidopropionyl-D-Lys)
Tesamorelintrans-3-hexenoyl-hGRF(1-44)NH₂
Molecular weight
Sermorelin~3358 Da
CJC-1295~3647 Da (DAC) / ~3367 Da (no-DAC)
Tesamorelin~5135 Da
Target area
SermorelinGH/IGF-1
CJC-1295GH/IGF-1
TesamorelinVisceral fat (HIV lipodystr.)
Storage
Sermorelin2–8°C (reconstituted)
CJC-12952–8°C (reconstituted)
Tesamorelin2–8°C (reconstituted)
Stability
Sermorelin14–21 days (reconstituted)
CJC-129525–30 days (reconstituted)
Tesamorelin~7 days (per label)

Sermorelin, CJC-1295 or Tesamorelin: how do they differ?

All three are versions of growth hormone-releasing hormone (GHRH), and all three prompt the pituitary gland to make growth hormone. They differ in structure: sermorelin is the stretch made of the first 29 amino acids of GHRH; CJC-1295 was altered so that it binds to one of the proteins in the blood, which is why it acts for days instead of minutes; tesamorelin is a stabilised, modified version of GHRH. Their status differs as well: the FDA previously approved sermorelin for growth hormone deficiency in children and approved tesamorelin in 2010 to reduce abdominal fat around the internal organs in HIV-associated lipodystrophy, while CJC-1295 is experimental, with only a few small human studies. The target row of the table reflects this: GH/IGF-1 for sermorelin and CJC-1295, fat around the internal organs for tesamorelin.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant